Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), allowing the company to proceed with Phase 2 clinical development of its lead multiple sclerosis (MS) candidate. The planned study will be a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological measures. Trial start-up activities, including site selection, are already underway, with patient enrollment and drug administration expected to begin as soon as possible.
The significance of this milestone lies in the mechanism of action of Lucid-MS, which is designed to provide neuroprotection by inhibiting demyelination—the process by which the protective myelin sheath around nerve fibers is damaged. This differentiates it from existing MS therapies that primarily focus on modulating the immune system. Lucid-MS targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. In preclinical models, the drug candidate has demonstrated the ability to prevent and reverse myelin breakdown, offering a potential disease-modifying approach that could address the underlying cause of disability accumulation in MS.
Prior Phase 1 trials in healthy participants have shown that Lucid-MS has a favorable safety profile and is well tolerated, supporting its advancement into later-stage testing. The company also reported having more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, providing a solid financial foundation to support the upcoming trial.
MS is a chronic, often disabling disease that affects the central nervous system, with current treatments largely aimed at reducing relapse rates and slowing progression through immune modulation. However, these treatments do not directly repair or protect myelin. Lucid-MS's neuroprotective approach holds promise for filling this therapeutic gap, potentially improving long-term outcomes for patients.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is dedicated to the research and development of Lucid-MS. The company also retains an ownership stake in Unbuzzd Wellness Inc., which markets an OTC version of its alcohol misuse product, and is entitled to royalty payments on sales of that product.
The FDA's clearance marks a critical regulatory milestone for Quantum BioPharma, moving Lucid-MS into a phase where its efficacy in patients will be rigorously evaluated. If successful, Lucid-MS could become a first-in-class therapy for MS, offering hope to millions of patients worldwide who currently lack options that directly target the neurodegenerative aspects of the disease. The initiation of Phase 2 trials is a key step in validating the compound's potential and advancing the company's pipeline.
